When stratified by different drug categories, it was indicated that when compared with non-bDMARD users, the risks of MI (OR = 0.74, 95% CI, 0.63 to 0.88, I2 = 27%), heart failure (OR = 0.83, 95% CI, 0.73 to 0.95, I2 = 43%), CV death (OR = 0.53, 95% CI, 0.33 to 0.86, I2 = 0%), and all-cause mortality (OR = 0.63, 95% CI, 0.47 to 0.84, I2 = 66%) were significantly decreased in TNF-α inhibitor users. The gene discussed is TNF; the disease is heart failure.